PC
IBB icon

Pecaut & Co’s iShares Biotechnology ETF IBB Stock Holding History

Pecaut & Co’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-302
Closed -$36.9K – 88
2023
Q3 		$36.9K Hold
302
– – 0.02% 89
2023
Q2 		$38.3K Sell
302
-53
-15% -$6.88K 0.02% 93
2023
Q1 		$45.9K Sell
355
-49
-12% -$6.41K 0.02% 96
2022
Q4 		$53K Sell
404
-387
-49% -$50K 0.03% 91
2022
Q3 		$93K Buy
+791
New +$98.2K 0.05% 80
2022
Q2 		– Sell
-1,058
Closed -$138K – 104
2022
Q1 		$138K Buy
+1,058
New +$138K 0.07% 80

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Pecaut & Co's IBB Position: Q4 2023 in Review

Pecaut & Co sold out of iShares Biotechnology ETF (IBB) in Q4 2023, closing a stake of 302 shares — an estimated $36.9K sold.

Pecaut & Co first reported a position in IBB in Q1 2022 and held it in 6 quarters. The position peaked at $138K in Q1 2022. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2023.

  • Pecaut & Co reported no remaining iShares Biotechnology ETF position as of Q4 2023 after selling out during the quarter.
  • Pecaut & Co sold 302 iShares Biotechnology ETF shares in Q4 2023, an estimated $36.9K.
  • Pecaut & Co first reported a position in iShares Biotechnology ETF in Q1 2022 and held it in 6 quarters.
  • Pecaut & Co's iShares Biotechnology ETF position peaked at $138K in Q1 2022.
  • 874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2023.

Based on Pecaut & Co's 13F filing for Q4 2023, filed 7 Feb 2024.